 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for EIF3L |
 Gene summary |
| Basic gene information | Gene symbol | EIF3L |
| Gene name | eukaryotic translation initiation factor 3, subunit L | |
| Synonyms | EIF3EIP|EIF3S11|EIF3S6IP|HSPC021|HSPC025|MSTP005 | |
| Cytomap | UCSC genome browser: 22q | |
| Type of gene | protein-coding | |
| RefGenes | NM_001242923.1, NM_016091.3, | |
| Description | eIEF associated protein HSPC021eukaryotic translation initiation factor 3 subunit 6-interacting proteineukaryotic translation initiation factor 3 subunit E-interacting proteineukaryotic translation initiation factor 3 subunit L | |
| Modification date | 20141207 | |
| dbXrefs | HGNC : HGNC | |
| Ensembl : ENSG00000100129 | ||
| HPRD : 10932 | ||
| Vega : OTTHUMG00000150671 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_EIF3L | |
| BioGPS: 51386 | ||
| Pathway | NCI Pathway Interaction Database: EIF3L | |
| KEGG: EIF3L | ||
| REACTOME: EIF3L | ||
| Pathway Commons: EIF3L | ||
| Context | iHOP: EIF3L | |
| ligand binding site mutation search in PubMed: EIF3L | ||
| UCL Cancer Institute: EIF3L | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | OvaryThymus | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | OVTHYM | |
| Reference showing the relevant tissue of EIF3L | ||
| Description by TissGene annotations | TissgsLTS Fused withTSGene Fused withOncogene | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID | GO:0006413 | translational initiation | 17581632 | GO:0006413 | translational initiation | 17581632 |
| Top |
| TissGeneExp for EIF3L |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| Top |
| TissGene-miRNA for EIF3L |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for EIF3L |
| TissGeneSNV for EIF3L |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.Y367H | COAD | 1 |
| p.R400C | ACC | 1 |
| p.A326T | SKCM | 1 |
| p.D524N | LUAD | 1 |
| p.A374T | SKCM | 1 |
| p.A337T | SARC | 1 |
| p.R391W | PCPG | 1 |
| p.R279H | KIRC | 1 |
| p.E232K | CESC | 1 |
| p.Y137* | PRAD | 1 |
| p.S8C | HNSC | 1 |
| p.L441M | BLCA | 1 |
| p.R216C | SKCM | 1 |
| p.Q282X | SKCM | 1 |
| p.R216C | BRCA | 1 |
| p.R333H | KIRP | 1 |
| p.P111S | ESCA | 1 |
| p.R105T | BLCA | 1 |
| p.N54D | LUSC | 1 |
| p.G146E | HNSC | 1 |
| p.P175R | LUAD | 1 |
| p.S238F | SARC | 1 |
| p.H232Y | BLCA | 1 |
| p.S217C | OV | 1 |
| p.T533I | SKCM | 1 |
| p.Q330* | SKCM | 1 |
| p.H263Q | DLBC | 1 |
| p.R279C | HNSC | 1 |
| p.E410D | LUSC | 1 |
| p.W222* | BLCA | 1 |
| p.R201H | UCEC | 1 |
| p.K419N | LUAD | 1 |
| p.G172R | KIRC | 1 |
| p.R328H | OV | 1 |
| p.I506V | LUAD | 1 |
| p.S462N | STAD | 1 |
| p.Q402H | BLCA | 1 |
| p.G505V | KIRC | 1 |
| p.G147E | LGG | 1 |
| p.S264F | HNSC | 1 |
| p.R352C | ACC | 1 |
| p.D524H | LUAD | 1 |
| p.R381H | KIRP | 1 |
| p.E134Q | BLCA | 1 |
| p.E250K | READ | 1 |
| p.E295D | UCEC | 1 |
| p.P120S | HNSC | 1 |
| p.E9K | BLCA | 1 |
| p.L457V | OV | 1 |
| Top |
| TissGeneCNV for EIF3L |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for EIF3L |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Chimerdb3.0 | ChiTaRs | NA | CB149589 | CCZ1B-EIF3L | chr7:6838807 | chr22:38245425 | |
| Chimerdb3.0 | ChiTaRs | NA | DA876636 | TMEM33-EIF3L | chr4:41958873 | chr22:38245426 | |
| Chimerdb3.0 | ChiTaRs | NA | DA039338 | EIF3L-MTUS1 | chr22:38247497 | chr8:17541953 | |
| Chimerdb3.0 | ChiTaRs | NA | BM561801 | EIF3L-SEPT6 | chr22:38284548 | chrX:118753550 | |
| Chimerdb3.0 | ChiTaRs | NA | AW022788 | EIF3L-EIF3L | chr22:38284512 | chr22:38284496 | |
| Chimerdb3.0 | ChiTaRs | NA | BF809008 | EIF3L-LOC440934 | chr22:38273852 | chr2:223186030 | |
| Chimerdb3.0 | ChiTaRs | NA | BC001814 | MARS-EIF3L | chr12:57883326 | chr22:38245441 | |
| Chimerdb3.0 | FusionScan | ESCA | TCGA-L5-A4OS-01A | EIF3L-TRIOBP | In-Frame | chr22:38274178 | chr22:38106433 |
| Chimerdb3.0 | FusionScan | LUAD | TCGA-69-7979-01A | EIF3L-VPS13B | Out-of-Frame | chr22:38251651 | chr8:100861003 |
| Chimerdb3.0 | FusionScan | DLBC | TCGA-G8-6325-01A | RAF1-EIF3L | In-Frame | chr3:12660013 | chr22:38282771 |
| Chimerdb3.0 | FusionScan | LUSC | TCGA-43-5668-01A | EIF3L-TRIOBP | In-Frame | chr22:38274178 | chr22:38147778 |
| TCGAfusionPortal | PRADA | LUAD | TCGA-44-A4SU-01A | EIF3L-ASCC2 | CDS-5UTR | Chr22:38251651 | Chr22:30228331 |
| Top |
| TissGeneNet for EIF3L |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| EIF3L, DNM2, SIRT7, TSG101, UBC, EIF1B, RGS2, SSSCA1, HDAC5, EIF3F, EIF3B, TMBIM4, B2M, EIF3E, XRN2, EIF3H, H2AFX, POLR1B, EIF3D, EIF4A2, EIF3K (tumor) | EIF3L, SIRT7, TSG101, UBC, EIF3A, EIF1B, RGS2, SMAD2, HDAC5, TADA2A, EIF3F, TMBIM4, B2M, EIF3E, GH1, EIF3H, HLA-C, RRN3, EIF3D, EIF4A2, EIF3K (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| EIF3L, DNM2, SIRT7, TSG101, UBC, SSSCA1, CUL1, SMAD2, HDAC5, EIF3F, B2M, EIF3E, GH1, XRN2, EIF3H, EIF3C, HLA-C, POLR1B, EIF3D, EIF4A2, EIF3K (tumor) | EIF3L, DNM2, SIRT7, UBC, EIF3A, EIF1B, RGS2, SMAD2, TADA2A, EIF3F, EIF3B, B2M, EIF3E, XRN2, EIF3H, H2AFX, HLA-C, POLR1B, EIF3D, EIF4A2, EIF3K (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| EIF3L, DNM2, SIRT7, TSG101, EIF3A, EIF1B, SSSCA1, SMAD2, HDAC5, EIF3F, TMBIM4, EIF3E, GH1, EIF3H, EIF3C, H2AFX, HLA-C, POLR1B, EIF3D, EIF4A2, EIF3K (tumor) | EIF3L, DNM2, SIRT7, TSG101, UBC, EIF3A, EIF1B, SMAD2, HDAC5, EIF3F, EIF3B, B2M, EIF3E, GH1, EIF3H, EIF3C, HLA-C, POLR1B, EIF3D, EIF4A2, EIF3K (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| EIF3L, DNM2, SIRT7, TSG101, EIF3A, SSSCA1, SMAD2, HDAC5, EIF3F, EIF3B, B2M, EIF3E, XRN2, EIF3H, EIF3C, H2AFX, HLA-C, RRN3, EIF3D, EIF4A2, EIF3K (tumor) | EIF3L, SIRT7, TSG101, EIF3A, EIF1B, CUL1, SMAD2, TADA2A, EIF3F, EIF3B, TMBIM4, EIF3E, XRN2, EIF3H, H2AFX, HLA-C, POLR1B, RRN3, EIF3D, EIF4A2, EIF3K (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| EIF3L, DNM2, SIRT7, TSG101, EIF3A, RGS2, SSSCA1, SMAD2, TADA2A, EIF3F, TMBIM4, B2M, EIF3E, GH1, EIF3H, H2AFX, HLA-C, RRN3, EIF3D, EIF4A2, EIF3K (tumor) | EIF3L, SIRT7, TSG101, EIF3A, EIF1B, RGS2, SMAD2, HDAC5, EIF3F, TMBIM4, EIF3E, GH1, XRN2, EIF3H, EIF3C, H2AFX, HLA-C, POLR1B, EIF3D, EIF4A2, EIF3K (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| EIF3L, DNM2, TSG101, UBC, EIF3A, RGS2, SSSCA1, CUL1, TADA2A, EIF3F, EIF3B, B2M, EIF3E, XRN2, EIF3H, H2AFX, HLA-C, POLR1B, RRN3, EIF3D, EIF4A2 (tumor) | EIF3L, DNM2, TSG101, UBC, EIF3A, EIF1B, SSSCA1, SMAD2, HDAC5, TADA2A, EIF3F, EIF3B, TMBIM4, B2M, EIF3E, EIF3H, EIF3C, HLA-C, EIF3D, EIF4A2, EIF3K (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| EIF3L, DNM2, SIRT7, TSG101, UBC, EIF1B, SSSCA1, CUL1, HDAC5, EIF3F, EIF3B, TMBIM4, B2M, EIF3E, GH1, EIF3H, EIF3C, HLA-C, EIF3D, EIF4A2, EIF3K (tumor) | EIF3L, SIRT7, TSG101, EIF1B, SSSCA1, CUL1, HDAC5, EIF3F, EIF3B, B2M, EIF3E, XRN2, EIF3H, EIF3C, H2AFX, HLA-C, POLR1B, RRN3, EIF3D, EIF4A2, EIF3K (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| EIF3L, DNM2, TSG101, UBC, EIF3A, EIF1B, SSSCA1, CUL1, HDAC5, TADA2A, EIF3F, TMBIM4, B2M, EIF3E, XRN2, EIF3H, EIF3C, RRN3, EIF3D, EIF4A2, EIF3K (tumor) | EIF3L, SIRT7, TSG101, UBC, EIF3A, EIF1B, CUL1, SMAD2, EIF3F, EIF3B, TMBIM4, EIF3E, XRN2, EIF3H, EIF3C, H2AFX, HLA-C, POLR1B, EIF3D, EIF4A2, EIF3K (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| EIF3L, DNM2, SIRT7, TSG101, UBC, EIF3A, RGS2, SSSCA1, SMAD2, HDAC5, EIF3F, TMBIM4, EIF3E, EIF3H, H2AFX, HLA-C, POLR1B, RRN3, EIF3D, EIF4A2, EIF3K (tumor) | EIF3L, DNM2, SIRT7, TSG101, EIF3A, EIF1B, SMAD2, HDAC5, TADA2A, EIF3F, EIF3B, B2M, EIF3E, XRN2, EIF3H, HLA-C, POLR1B, RRN3, EIF3D, EIF4A2, EIF3K (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| EIF3L, DNM2, SIRT7, TSG101, EIF3A, EIF1B, SSSCA1, HDAC5, TADA2A, EIF3F, EIF3B, EIF3E, GH1, XRN2, EIF3H, H2AFX, HLA-C, RRN3, EIF3D, EIF4A2, EIF3K (tumor) | EIF3L, DNM2, SIRT7, TSG101, EIF3A, SSSCA1, CUL1, HDAC5, TADA2A, EIF3F, EIF3B, B2M, EIF3E, XRN2, EIF3H, EIF3C, HLA-C, RRN3, EIF3D, EIF4A2, EIF3K (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| EIF3L, DNM2, SIRT7, TSG101, EIF1B, RGS2, SSSCA1, CUL1, SMAD2, HDAC5, TADA2A, EIF3F, B2M, EIF3E, XRN2, EIF3H, EIF3C, H2AFX, HLA-C, RRN3, EIF4A2 (tumor) | EIF3L, SIRT7, TSG101, UBC, EIF1B, RGS2, CUL1, SMAD2, EIF3F, TMBIM4, B2M, EIF3E, XRN2, EIF3H, H2AFX, HLA-C, POLR1B, RRN3, EIF3D, EIF4A2, EIF3K (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| EIF3L, DNM2, SIRT7, TSG101, UBC, EIF3A, RGS2, SMAD2, TADA2A, EIF3F, EIF3B, EIF3E, XRN2, EIF3H, EIF3C, H2AFX, POLR1B, RRN3, EIF3D, EIF4A2, EIF3K (tumor) | EIF3L, DNM2, SIRT7, TSG101, UBC, EIF3A, EIF1B, SMAD2, EIF3F, EIF3B, TMBIM4, EIF3E, GH1, XRN2, EIF3H, H2AFX, POLR1B, RRN3, EIF3D, EIF4A2, EIF3K (normal) |
 |  |
| Top |
| TissGeneProg for EIF3L |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for EIF3L |
| TissGeneDrug for EIF3L |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for EIF3L |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |